<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20160131026279N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-05-05</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Effect of rehabilitation on treatment of mild cognitive impairment</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of galvanic vestibular stimulation and vestibular rehabilitation on spatial memory of patients with amnestic mild cognitive impairment</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-09-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>48</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/47249</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Randomization method: Individual random assignment to four equal groups with block randomization method using blocks of size 4; Randomization and random sequential allocation: done with Random Allocation Software; Allocation concealment: done with sequentially numbered, sealed, opaque envelopes.</study_design>
      <phase>N/A</phase>
      <hc_freetext>amnestic mild cognitive impairment.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: receiving GVS and VR, GVS: Subliminal noisy GVS, 20 min, once a week, three sessions. VR: Cooksey-Cawthorne rehabilitation exercises, 30 min, twice a day for one month. Intervention 2: Intervention group 2: receiving VR only. VR: Cooksey-Cawthorne rehabilitation exercises, 30 min, twice a day for one month. Intervention 3: Intervention group 3: receiving GVS only. GVS: Subliminal noisy GVS, 20 min, once a week, three sessions. Intervention 4: Control group: no intervention.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is -</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mansoureh Adel Ghahraman</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Enghelab Ave.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1148956111</zip>
        <telephone>+98 21 7753 4364</telephone>
        <email>madel@tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mansoureh Adel Ghahraman</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Enghelab Ave.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1148956111</zip>
        <telephone>+98 21 7753 4364</telephone>
        <email>madel@tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Diagnosed with aMCI
MMSE test score &lt;21 for participants with primary school education and &lt;23 for participants with a university degree
MoCA test score between 19 and 24
Adequate visuomotor coordination based on the standard score (Z Score ± 1) in motor screening task (MOT) test
Normal or modified visual acuity or with glasses (20/20) using the Snellen chart in order to correctly diagnose CANTAB test forms
Normal hearing ability or corrected hearing loss with hearing aid to hear the stimulus in the force plate test</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Color blindness according to Ishihara test for color blindness
Neck pain or limitation in neck range of motion
Anticholinergic drug consumption (e.g. hyoscine and atropine) consumption
Consumption of drugs affecting vestibulo-ocular reflex such as Cinnarizine , betahistine, painkillers, and tranquilizers from 48 hours prior to tests
History of orthopedic problems in the last 6 months (lower extremity fractures, dislocation, and pain)
Obvious lower extremity deformities such as scoliosis and kyphosis according to observation of a physiotherapist
History of rheumatic and/or metabolic diseases
History of alcoholism or addiction</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G31.84</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Mild cognitive impairment, so stated</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: receiving GVS and VR, GVS: Subliminal noisy GVS, 20 min, once a week, three sessions. VR: Cooksey-Cawthorne rehabilitation exercises, 30 min, twice a day for one month</i_keyword>
      <i_keyword>Intervention group 2: receiving VR only. VR: Cooksey-Cawthorne rehabilitation exercises, 30 min, twice a day for one month</i_keyword>
      <i_keyword>Intervention group 3: receiving GVS only. GVS: Subliminal noisy GVS, 20 min, once a week, three sessions.</i_keyword>
      <i_keyword>Control group: no intervention</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Montreal Cognitive Assessment score. Timepoint: Before, immediately after the end of the intervention period, and one month later. Method of measurement: Montreal Cognitive Assessment (MoCA).</prim_outcome>
      <prim_outcome>Learning score. Timepoint: Before, immediately after the end of the intervention period, and one month later. Method of measurement: Rey Auditory Verbal Learning Test.</prim_outcome>
      <prim_outcome>Immediate recall score. Timepoint: Before, immediately after the end of the intervention period, and one month later. Method of measurement: Rey Auditory Verbal Learning Test.</prim_outcome>
      <prim_outcome>Delayed recall score. Timepoint: Before, immediately after the end of the intervention period, and one month later. Method of measurement: Rey Auditory Verbal Learning Test.</prim_outcome>
      <prim_outcome>Percentage of correct answers in pattern recognition memory (PRM). Timepoint: Before, immediately after the end of the intervention period, and one month later. Method of measurement: CANTAB test.</prim_outcome>
      <prim_outcome>Response latency in Delayed Matching to Sample. Timepoint: Before, immediately after the end of the intervention period, and one month later. Method of measurement: CANTAB test.</prim_outcome>
      <prim_outcome>Percentage of correct selection in Delayed Matching to Sample. Timepoint: Before, immediately after the end of the intervention period, and one month later. Method of measurement: CANTAB test.</prim_outcome>
      <prim_outcome>Percentage of errors in Paired Associates Learning. Timepoint: Before, immediately after the end of the intervention period, and one month later. Method of measurement: CANTAB test.</prim_outcome>
      <prim_outcome>Spatial Span length. Timepoint: Before, immediately after the end of the intervention period, and one month later. Method of measurement: CANTAB test.</prim_outcome>
      <prim_outcome>Vestibulo-ocular reflex gain. Timepoint: Before, immediately after the end of the intervention period, and one month later. Method of measurement: video head impulse test (vHIT).</prim_outcome>
      <prim_outcome>Percentage of overt saccades. Timepoint: Before, immediately after the end of the intervention period, and one month later. Method of measurement: video head impulse test (vHIT).</prim_outcome>
      <prim_outcome>Percentage of covert saccades. Timepoint: Before, immediately after the end of the intervention period, and one month later. Method of measurement: video head impulse test (vHIT).</prim_outcome>
      <prim_outcome>Vestibulo-ocular reflex gain asymmetry. Timepoint: Before, immediately after the end of the intervention period, and one month later. Method of measurement: video head impulse test (vHIT).</prim_outcome>
      <prim_outcome>Displacement of center of pressure in both anterior-posterior and medial-lateral directions in anticipation, weight transfer, and locomotion. Timepoint: Before, immediately after the end of the intervention period, and one month later. Method of measurement: force-plate test.</prim_outcome>
      <prim_outcome>Velocity of displacement of center of pressure in both anterior-posterior and medial-lateral directions in anticipation, weight transfer, and locomotion. Timepoint: Before, immediately after the end of the intervention period, and one month later. Method of measurement: force-plate test.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-02-19</approval_date>
        <contact_name>Ethics committee of School of Nursing and Midwifery &amp; Rehabilitation ,Tehran University of Medical S</contact_name>
        <contact_address>Enghelab Ave. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
